Indiviorplc (IZQVF) 3.8600 $IZQVF
IntelGenx Announces Notice of Appeal for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
Marketwire Canada - Mon Jul 11, 3:00PM CDT
SAINT-LAURENT, QUEBEC--(Marketwired - Jul 11, 2016) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the receipt of the recent notice of appeal for the buprenorphine/naloxone sublingual film product for the treatment of opiate addiction by Par Pharmaceutical, Inc. and IntelGenx Corp. to the United States Court of Appeals for the Federal Circuit from the final judgment issued by the U.S. District Court for the District of Delaware on June 28, 2016.
IGX.VN: 0.960 (+0.080)
Indivior to Present New Data at ISPOR and ICOO that Assess Implications of Adherence, Healthcare Service Utilization and Costs in Opioid Use Disorder
PR Newswire - Fri May 20, 10:29AM CDT
Indivior PLC (LON: INDV) will unveil new real-world data that assess relapse and Buprenorphine Medication-Assisted Treatment (B-MAT) adherence rates and healthcare service utilization costs in addition to optimal minimal length of treatment, highlighting the company's continued dedication to ongoing research in opioid use disorder (OUD). Five posters will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual Meeting, to be held May 21-25, 2016 in Washington, DC along with two poster session presentations at the 2016 International Conference on Opioids (ICOO), June 5-7 in Boston, Massachusetts.
Indivior Presents Late-Breaking, Real-World Data Revealing Less than Half of Patients with Opioid Use Disorder Receive Medication-Assisted Treatment
PR Newswire - Fri Apr 15, 11:00AM CDT
Indivior Inc., a subsidiary of Indivior PLC (LON: INDV), presented new research from an analysis of more than 100,000 commercially insured patients indicating underutilization of treatment methods for patients with opioid use disorder (OUD), suggesting a growing need for improved access to medication-assisted treatment (MAT). Findings were presented in a poster session today at the American Society of Addiction Medicine 47th Annual Conference in Baltimore.
Addiction Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/m28s26/addiction) has announced the addition of the "Addiction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Addiction Overview - Therapeutics Development - Pipeline Products for Addiction - Overview - Pipeline Products for Addiction - Comparative Analysis - Addiction - Therapeutics under Development by Companies - Addiction - Therapeutics under Investigation by Universities/Institutes - Addiction - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Addiction - Products under Development by Companies - Addiction - Products under Investigation by Universities/Institutes - Addiction - Companies Involved in Therapeutics Development Companies Mentioned - AbbVie Inc. - Addex Therapeutics Ltd - Adial Pharmaceuticals, LLC - Aelis Farma S.A.S. - Alkermes Plc - Aphios Corporation - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astellas Pharma Inc. - C4X Discovery Limited - Camurus AB - Embera NeuroTherapeutics, Inc. - Ethypharm S.A. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Grunenthal GmbH - H. Lundbeck A/S - Heptares Therapeutics Limited - Heron Therapeutics, Inc. - Immunovaccine, Inc. - Indivior Plc - INSYS Therapeutics, Inc. - InterveXion Therapeutics LLC - Neurocrine Biosciences, Inc. - Omeros Corporation - P2D Bioscience - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Tonix Pharmaceuticals Holding Corp. - VM Discovery, Inc. - XenoPort, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/m28s26/addiction
PFE: 35.44 (+0.29), ALKS: 48.59 (-0.32), ZYNE: 9.99 (-0.51), XNPT: 7.07 (+0.05), OMER: 12.50 (+0.28), INSY: 17.62 (+0.32), NBIX: 49.97 (-0.11), TNXP: 2.07 (+0.04), HRTX: 18.90 (-0.04), ABBV: 66.54 (+0.44), ARNA: 1.74 (+0.03)
Substance (Drug) Abuse - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/lpcvdl/substance_drug) has announced the addition of the "Substance (Drug) Abuse - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Substance (Drug) Abuse's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope of the Report: - The report provides a snapshot of the global therapeutic landscape of Substance (Drug) Abuse - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Substance (Drug) Abuse pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Addex Therapeutics Ltd - Aelis Farma S.A.S. - Astraea Therapeutics, LLC - Cerecor Inc. - Foresee Pharmaceuticals, LLC - Grunenthal GmbH - Indivior Plc - InterveXion Therapeutics LLC - P2D Bioscience - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lp...tance_drug
CERCU: 5.03 (-0.56), ZYNE: 9.99 (-0.51)
Alcohol Addiction - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/gblcff/alcohol_addiction) has announced the addition of the "Alcohol Addiction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcohol Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AbbVie Inc. - Addex Therapeutics Ltd - Adial Pharmaceuticals, LLC - Arbutus Biopharma Corporation - Astraea Therapeutics, LLC - AstraZeneca Plc - Bionex Pharmaceuticals LLC - Cerecor Inc. - Curemark, LLC - Eli Lilly and Company - Ethypharm S.A. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - H. Lundbeck A/S - Indivior Plc - Johnson & Johnson - Kyorin Pharmaceutical Co., Ltd. - Lohocla Research Corporation - Neurocrine Biosciences, Inc. - Omeros Corporation - Pfizer Inc. - RTI International - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Tonix Pharmaceuticals Holding Corp. - VM Discovery, Inc. - XenoPort, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/gb..._addiction
PFE: 35.44 (+0.29), LLY: 81.56 (-0.86), ZYNE: 9.99 (-0.51), XNPT: 7.07 (+0.05), OMER: 12.50 (+0.28), ABUS: 4.02 (-0.35), CERCU: 5.03 (-0.56), JNJ: 124.24 (+0.38), NBIX: 49.97 (-0.11), TNXP: 2.07 (+0.04), AZN: 34.28 (-0.02), ABBV: 66.54 (+0.44)
XenoPort Reports Third Quarter Financial Results
BusinessWire - Wed Nov 04, 3:05PM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the third quarter and nine months ended September 30, 2015. Net product sales for HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets nearly doubled to $11.0 million for the third quarter of 2015 compared to $5.6 million for the same period in 2014. Total revenues for the third quarter were $11.4 million compared to $31.1 million for the same period in 2014. Revenues for the third quarter of 2014 included $25.0 million in collaboration revenue resulting from XenoPort's license agreement with Indivior PLC. Net loss for the third quarter was $24.1 million compared to net income of $8.3 million for the same period in 2014. At September 30, 2015, XenoPort had cash, cash equivalents and short-term investments of $152.4 million.
XNPT: 7.07 (+0.05)
Indivior Applauds Recent Momentum to Address Opioid Dependence and Overdose Epidemic
PR Newswire - Wed Oct 21, 8:35PM CDT
Indivior PLC (LON: INDV) is encouraged by recent efforts at the federal, state and local levels of government to expand access to treatment options as a means to help address the growing opioid dependence and overdose epidemic. The White House announcement of its plan to help reduce the rise in deaths from drug-related overdoses is another important step to confront this significant public health crisis. Efforts include providing greater access to treatment for opioid dependence, training to properly prescribe opioid medications and increasing availability of naloxone.
Indivior PLC Responds to Court's Decision on Motion to Amend
PR Newswire - Mon Oct 12, 7:10AM CDT
Indivior PLC (LON: INDV) today announced that the U.S. District Court for the District of Delaware granted the Company's motion to amend its complaint to specifically refer to Teva Pharmaceuticals' Abbreviated New Drug Application (ANDA) No. 205299 to market a generic equivalent of two of the strengths of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in the United States.
Esophagitis Global Clinical Trials Review, H1, 2015 - Clinical Trial Overview of Top Companies
M2 - Thu Aug 13, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/582llc/esophagitis) has announced the addition of the "Esophagitis Global Clinical Trials Review, H1, 2015" report to their offering. Esophagitis Global Clinical Trials Review, H1, 2015 Summary Our clinical trial report, Esophagitis Global Clinical Trials Review, H1, 2015" provides data on the Esophagitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Esophagitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Esophagitis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - AstraZeneca PLC - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Johnson & Johnson - Pfizer Inc. - Indivior PLC - Novartis AG - Shire Plc - Yuhan Corporation - Dr. Reddy's Laboratories Limited Clinical Trial Overview of Top Institutes / Government - Mayo Clinic - Shimane University - Academic Medical Center - The University of Utah - Cincinnati Children's Hospital Medical Center - Juntendo University School of Medicine - Osaka City University - Seoul National University Hospital - University of North Carolina - Yokohama City University - Five Key Clinical Profiles For more information visit http://www.researchandmarkets.com/research/58...sophagitis
JNJ: 124.24 (+0.38), SHPG: 200.87 (+0.28), PFE: 35.44 (+0.29), AZN: 34.28 (-0.02), NVS: 83.12 (+0.22)
Hepatic Injury Global Clinical Trials Review, H1, 2015 - Clinical Trial Overview of Top Companies
M2 - Tue Aug 11, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4z6qk9/hepatic_injury) has announced the addition of the "Hepatic Injury Global Clinical Trials Review, H1, 2015" report to their offering. This report provides data on the Hepatic Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatic Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatic Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Pfizer Inc. - Ocera Therapeutics, Inc. - Novartis AG - McNEIL-PPC, Inc. - Jubilant Life Sciences Limited - Indivior PLC - Ikaria Holdings, Inc. - Golden Biotechnology Corp. - Cumberland Pharmaceuticals, Inc. Clinical Trial Overview of Top Institutes / Government - Children's Medical Center - Chonbuk National University Hospital - Denver Health and Hospital Authority - Hillerod Hospital - Seoul National University Hospital - The First Affiliated Hospital of Sun Yat-sen University - Thomas Jefferson University - University of Alabama at Birmingham - University of Texas Southwestern Medical Center at Dallas For more information visit http://www.researchandmarkets.com/research/4z...tic_injury
PFE: 35.44 (+0.29), OCRX: 2.40 (-0.16), CPIX: 4.63 (+0.03), NVS: 83.12 (+0.22)
Global Esophageal Diseases Clinical Trials Review, H1, 2015 - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
M2 - Wed Aug 05, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pwhdpj/esophageal) has announced the addition of the "Esophageal Diseases Global Clinical Trials Review, H1, 2015" report to their offering. Esophageal Diseases Global Clinical Trials Review, H1, 2015 provides data on the Esophageal Diseases clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Esophageal Diseases. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Esophageal Diseases. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Esophageal Diseases Therapeutics Clinical Trials - AstraZeneca PLC - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Johnson & Johnson - Pfizer Inc. - Indivior PLC - Novartis AG - Shire Plc - Yuhan Corporation - Dr. Reddy's Laboratories Limited Clinical Trial Overview of Top Institutes / Government - Mayo Clinic - Shimane University - Academic Medical Center - The University of Utah - Zhongshan Hospital - Chinese University of Hong Kong - Cincinnati Children's Hospital Medical Center - Department of Health, UK - Hyogo College Of Medicine - Juntendo University School of Medicine For more information visit http://www.researchandmarkets.com/research/pwhdpj/esophageal
JNJ: 124.24 (+0.38), SHPG: 200.87 (+0.28), PFE: 35.44 (+0.29), AZN: 34.28 (-0.02), NVS: 83.12 (+0.22)
Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review
PR Newswire - Wed Jul 29, 7:00AM CDT
Indivior PLC (LON: INDV) today announced that the New Drug Application (NDA) for naloxone nasal spray was accepted and received Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of opioid overdose. This naloxone nasal spray comes as a pre-filled device that contains naloxone specially formulated for optimal absorption into the nasal mucosa.1 The device has been designed to require minimal training so individuals may be better equipped to help an opioid overdose victim.
Global Opium (Opioid) Addiction Pipeline Review, H1 2015 - 15 Companies & 20 Drug Profiles
M2 - Wed Jun 10, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhxtt9/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Camurus AB - Celtic Pharmaceutical Holdings L.P. - D&A Pharma SAS - Foresee Pharmaceuticals, LLC - Heron Therapeutics, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Omeros Corporation - Pfizer Inc. - Relmada Therapeutics, Inc. - Titan Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - (buprenorphine hydrochloride naloxone hydrochloride) - Buprenorphine Hemiadipate Hydrochloride - buprenorphine hydrochloride - buprenorphine hydrochloride depot - buprenorphine hydrochloride ER - buprenorphine hydrochloride long acting - buprenorphine hydrochloride SR - cannabidiol - FP-004 - MAL - methadone IR - naltrexone - naltrexone - OMS-405 - OMS-527 - PF-5006739 - samidorphan - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - TA-CD - Vaccine for Opium Addiction For more information visit http://www.researchandmarkets.com/research/hh...ium_opioid
BDSI: 2.47 (+0.02), INSY: 17.62 (+0.32), HRTX: 18.90 (-0.04), PFE: 35.44 (+0.29), ALKS: 48.59 (-0.32), ACUR: 1.85 (-0.01), OMER: 12.50 (+0.28)
Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 2.47 (+0.02), PFE: 35.44 (+0.29), LLY: 81.56 (-0.86), GSK: 44.89 (-0.19), ACUR: 1.85 (-0.01), JNJ: 124.24 (+0.38), INSY: 17.62 (+0.32), TRGT: 0.96 (-1.25), GILD: 80.41 (+0.64), AZN: 34.28 (-0.02), ABBV: 66.54 (+0.44), ARNA: 1.74 (+0.03)
Indivior PLC Announces Positive Top-line Results From Pivotal Phase 3 Trial of RBP-7000 in Schizophrenia
PR Newswire - Tue May 05, 6:00AM CDT
Indivior PLC (LON: INDV) today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period. Symptom reduction was measured using the change from baseline to end of treatment in the total Positive and Negative Syndrome Scale (PANSS) scores. RBP-7000 also met the key secondary endpoint with statistically significant improvements in the Clinical Global Impression-Severity of Illness (CGI-S) scale compared with placebo over the 8-week treatment period using change from baseline to end of treatment.
IntelGenx Announces Notice of Appeal for Buprenorphine/Naloxone Sublingual Film Product for the Treatment of Opiate Addiction
Marketwire Canada - Mon Jul 11, 3:00PM CDT
SAINT-LAURENT, QUEBEC--(Marketwired - Jul 11, 2016) - IntelGenx Corp. (TSX VENTURE:IGX)(OTCQX:IGXT), today announced the receipt of the recent notice of appeal for the buprenorphine/naloxone sublingual film product for the treatment of opiate addiction by Par Pharmaceutical, Inc. and IntelGenx Corp. to the United States Court of Appeals for the Federal Circuit from the final judgment issued by the U.S. District Court for the District of Delaware on June 28, 2016.
IGX.VN: 0.960 (+0.080)
Indivior to Present New Data at ISPOR and ICOO that Assess Implications of Adherence, Healthcare Service Utilization and Costs in Opioid Use Disorder
PR Newswire - Fri May 20, 10:29AM CDT
Indivior PLC (LON: INDV) will unveil new real-world data that assess relapse and Buprenorphine Medication-Assisted Treatment (B-MAT) adherence rates and healthcare service utilization costs in addition to optimal minimal length of treatment, highlighting the company's continued dedication to ongoing research in opioid use disorder (OUD). Five posters will be presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 21st Annual Meeting, to be held May 21-25, 2016 in Washington, DC along with two poster session presentations at the 2016 International Conference on Opioids (ICOO), June 5-7 in Boston, Massachusetts.
Indivior Presents Late-Breaking, Real-World Data Revealing Less than Half of Patients with Opioid Use Disorder Receive Medication-Assisted Treatment
PR Newswire - Fri Apr 15, 11:00AM CDT
Indivior Inc., a subsidiary of Indivior PLC (LON: INDV), presented new research from an analysis of more than 100,000 commercially insured patients indicating underutilization of treatment methods for patients with opioid use disorder (OUD), suggesting a growing need for improved access to medication-assisted treatment (MAT). Findings were presented in a poster session today at the American Society of Addiction Medicine 47th Annual Conference in Baltimore.
Addiction Therapeutics Development Pipeline Review, H2 2015
M2 - Tue Feb 09, 6:40AM CST
Research and Markets (http://www.researchandmarkets.com/research/m28s26/addiction) has announced the addition of the "Addiction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Addiction Overview - Therapeutics Development - Pipeline Products for Addiction - Overview - Pipeline Products for Addiction - Comparative Analysis - Addiction - Therapeutics under Development by Companies - Addiction - Therapeutics under Investigation by Universities/Institutes - Addiction - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Addiction - Products under Development by Companies - Addiction - Products under Investigation by Universities/Institutes - Addiction - Companies Involved in Therapeutics Development Companies Mentioned - AbbVie Inc. - Addex Therapeutics Ltd - Adial Pharmaceuticals, LLC - Aelis Farma S.A.S. - Alkermes Plc - Aphios Corporation - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astellas Pharma Inc. - C4X Discovery Limited - Camurus AB - Embera NeuroTherapeutics, Inc. - Ethypharm S.A. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Grunenthal GmbH - H. Lundbeck A/S - Heptares Therapeutics Limited - Heron Therapeutics, Inc. - Immunovaccine, Inc. - Indivior Plc - INSYS Therapeutics, Inc. - InterveXion Therapeutics LLC - Neurocrine Biosciences, Inc. - Omeros Corporation - P2D Bioscience - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Tonix Pharmaceuticals Holding Corp. - VM Discovery, Inc. - XenoPort, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/m28s26/addiction
PFE: 35.44 (+0.29), ALKS: 48.59 (-0.32), ZYNE: 9.99 (-0.51), XNPT: 7.07 (+0.05), OMER: 12.50 (+0.28), INSY: 17.62 (+0.32), NBIX: 49.97 (-0.11), TNXP: 2.07 (+0.04), HRTX: 18.90 (-0.04), ABBV: 66.54 (+0.44), ARNA: 1.74 (+0.03)
Substance (Drug) Abuse - Pipeline Review, H2 2015
M2 - Thu Dec 17, 2:33AM CST
Research and Markets (http://www.researchandmarkets.com/research/lpcvdl/substance_drug) has announced the addition of the "Substance (Drug) Abuse - Pipeline Review, H2 2015" report to their offering. The report provides an overview of the Substance (Drug) Abuse's therapeutic pipeline. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope of the Report: - The report provides a snapshot of the global therapeutic landscape of Substance (Drug) Abuse - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Substance (Drug) Abuse pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - Addex Therapeutics Ltd - Aelis Farma S.A.S. - Astraea Therapeutics, LLC - Cerecor Inc. - Foresee Pharmaceuticals, LLC - Grunenthal GmbH - Indivior Plc - InterveXion Therapeutics LLC - P2D Bioscience - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/lp...tance_drug
CERCU: 5.03 (-0.56), ZYNE: 9.99 (-0.51)
Alcohol Addiction - Pipeline Review, H2 2015
M2 - Mon Nov 09, 9:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/gblcff/alcohol_addiction) has announced the addition of the "Alcohol Addiction - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcohol Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - AbbVie Inc. - Addex Therapeutics Ltd - Adial Pharmaceuticals, LLC - Arbutus Biopharma Corporation - Astraea Therapeutics, LLC - AstraZeneca Plc - Bionex Pharmaceuticals LLC - Cerecor Inc. - Curemark, LLC - Eli Lilly and Company - Ethypharm S.A. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - H. Lundbeck A/S - Indivior Plc - Johnson & Johnson - Kyorin Pharmaceutical Co., Ltd. - Lohocla Research Corporation - Neurocrine Biosciences, Inc. - Omeros Corporation - Pfizer Inc. - RTI International - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Tonix Pharmaceuticals Holding Corp. - VM Discovery, Inc. - XenoPort, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/gb..._addiction
PFE: 35.44 (+0.29), LLY: 81.56 (-0.86), ZYNE: 9.99 (-0.51), XNPT: 7.07 (+0.05), OMER: 12.50 (+0.28), ABUS: 4.02 (-0.35), CERCU: 5.03 (-0.56), JNJ: 124.24 (+0.38), NBIX: 49.97 (-0.11), TNXP: 2.07 (+0.04), AZN: 34.28 (-0.02), ABBV: 66.54 (+0.44)
XenoPort Reports Third Quarter Financial Results
BusinessWire - Wed Nov 04, 3:05PM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today financial results for the third quarter and nine months ended September 30, 2015. Net product sales for HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets nearly doubled to $11.0 million for the third quarter of 2015 compared to $5.6 million for the same period in 2014. Total revenues for the third quarter were $11.4 million compared to $31.1 million for the same period in 2014. Revenues for the third quarter of 2014 included $25.0 million in collaboration revenue resulting from XenoPort's license agreement with Indivior PLC. Net loss for the third quarter was $24.1 million compared to net income of $8.3 million for the same period in 2014. At September 30, 2015, XenoPort had cash, cash equivalents and short-term investments of $152.4 million.
XNPT: 7.07 (+0.05)
Indivior Applauds Recent Momentum to Address Opioid Dependence and Overdose Epidemic
PR Newswire - Wed Oct 21, 8:35PM CDT
Indivior PLC (LON: INDV) is encouraged by recent efforts at the federal, state and local levels of government to expand access to treatment options as a means to help address the growing opioid dependence and overdose epidemic. The White House announcement of its plan to help reduce the rise in deaths from drug-related overdoses is another important step to confront this significant public health crisis. Efforts include providing greater access to treatment for opioid dependence, training to properly prescribe opioid medications and increasing availability of naloxone.
Indivior PLC Responds to Court's Decision on Motion to Amend
PR Newswire - Mon Oct 12, 7:10AM CDT
Indivior PLC (LON: INDV) today announced that the U.S. District Court for the District of Delaware granted the Company's motion to amend its complaint to specifically refer to Teva Pharmaceuticals' Abbreviated New Drug Application (ANDA) No. 205299 to market a generic equivalent of two of the strengths of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in the United States.
Esophagitis Global Clinical Trials Review, H1, 2015 - Clinical Trial Overview of Top Companies
M2 - Thu Aug 13, 5:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/582llc/esophagitis) has announced the addition of the "Esophagitis Global Clinical Trials Review, H1, 2015" report to their offering. Esophagitis Global Clinical Trials Review, H1, 2015 Summary Our clinical trial report, Esophagitis Global Clinical Trials Review, H1, 2015" provides data on the Esophagitis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Esophagitis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Esophagitis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies - AstraZeneca PLC - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Johnson & Johnson - Pfizer Inc. - Indivior PLC - Novartis AG - Shire Plc - Yuhan Corporation - Dr. Reddy's Laboratories Limited Clinical Trial Overview of Top Institutes / Government - Mayo Clinic - Shimane University - Academic Medical Center - The University of Utah - Cincinnati Children's Hospital Medical Center - Juntendo University School of Medicine - Osaka City University - Seoul National University Hospital - University of North Carolina - Yokohama City University - Five Key Clinical Profiles For more information visit http://www.researchandmarkets.com/research/58...sophagitis
JNJ: 124.24 (+0.38), SHPG: 200.87 (+0.28), PFE: 35.44 (+0.29), AZN: 34.28 (-0.02), NVS: 83.12 (+0.22)
Hepatic Injury Global Clinical Trials Review, H1, 2015 - Clinical Trial Overview of Top Companies
M2 - Tue Aug 11, 3:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4z6qk9/hepatic_injury) has announced the addition of the "Hepatic Injury Global Clinical Trials Review, H1, 2015" report to their offering. This report provides data on the Hepatic Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hepatic Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hepatic Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more Clinical Trial Overview of Top Companies - Takeda Pharmaceutical Company Limited - Pfizer Inc. - Ocera Therapeutics, Inc. - Novartis AG - McNEIL-PPC, Inc. - Jubilant Life Sciences Limited - Indivior PLC - Ikaria Holdings, Inc. - Golden Biotechnology Corp. - Cumberland Pharmaceuticals, Inc. Clinical Trial Overview of Top Institutes / Government - Children's Medical Center - Chonbuk National University Hospital - Denver Health and Hospital Authority - Hillerod Hospital - Seoul National University Hospital - The First Affiliated Hospital of Sun Yat-sen University - Thomas Jefferson University - University of Alabama at Birmingham - University of Texas Southwestern Medical Center at Dallas For more information visit http://www.researchandmarkets.com/research/4z...tic_injury
PFE: 35.44 (+0.29), OCRX: 2.40 (-0.16), CPIX: 4.63 (+0.03), NVS: 83.12 (+0.22)
Global Esophageal Diseases Clinical Trials Review, H1, 2015 - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
M2 - Wed Aug 05, 8:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pwhdpj/esophageal) has announced the addition of the "Esophageal Diseases Global Clinical Trials Review, H1, 2015" report to their offering. Esophageal Diseases Global Clinical Trials Review, H1, 2015 provides data on the Esophageal Diseases clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Esophageal Diseases. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Esophageal Diseases. Reasons to buy - Understand the dynamics of a particular indication in a condensed manner - Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more - Obtain discontinued trial listing for trials across the globe - Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies Top Companies Participating in Esophageal Diseases Therapeutics Clinical Trials - AstraZeneca PLC - Takeda Pharmaceutical Company Limited - Eisai Co., Ltd. - Johnson & Johnson - Pfizer Inc. - Indivior PLC - Novartis AG - Shire Plc - Yuhan Corporation - Dr. Reddy's Laboratories Limited Clinical Trial Overview of Top Institutes / Government - Mayo Clinic - Shimane University - Academic Medical Center - The University of Utah - Zhongshan Hospital - Chinese University of Hong Kong - Cincinnati Children's Hospital Medical Center - Department of Health, UK - Hyogo College Of Medicine - Juntendo University School of Medicine For more information visit http://www.researchandmarkets.com/research/pwhdpj/esophageal
JNJ: 124.24 (+0.38), SHPG: 200.87 (+0.28), PFE: 35.44 (+0.29), AZN: 34.28 (-0.02), NVS: 83.12 (+0.22)
Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review
PR Newswire - Wed Jul 29, 7:00AM CDT
Indivior PLC (LON: INDV) today announced that the New Drug Application (NDA) for naloxone nasal spray was accepted and received Priority Review by the U.S. Food and Drug Administration (FDA) for the treatment of opioid overdose. This naloxone nasal spray comes as a pre-filled device that contains naloxone specially formulated for optimal absorption into the nasal mucosa.1 The device has been designed to require minimal training so individuals may be better equipped to help an opioid overdose victim.
Global Opium (Opioid) Addiction Pipeline Review, H1 2015 - 15 Companies & 20 Drug Profiles
M2 - Wed Jun 10, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhxtt9/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Camurus AB - Celtic Pharmaceutical Holdings L.P. - D&A Pharma SAS - Foresee Pharmaceuticals, LLC - Heron Therapeutics, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Omeros Corporation - Pfizer Inc. - Relmada Therapeutics, Inc. - Titan Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - (buprenorphine hydrochloride naloxone hydrochloride) - Buprenorphine Hemiadipate Hydrochloride - buprenorphine hydrochloride - buprenorphine hydrochloride depot - buprenorphine hydrochloride ER - buprenorphine hydrochloride long acting - buprenorphine hydrochloride SR - cannabidiol - FP-004 - MAL - methadone IR - naltrexone - naltrexone - OMS-405 - OMS-527 - PF-5006739 - samidorphan - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - TA-CD - Vaccine for Opium Addiction For more information visit http://www.researchandmarkets.com/research/hh...ium_opioid
BDSI: 2.47 (+0.02), INSY: 17.62 (+0.32), HRTX: 18.90 (-0.04), PFE: 35.44 (+0.29), ALKS: 48.59 (-0.32), ACUR: 1.85 (-0.01), OMER: 12.50 (+0.28)
Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 2.47 (+0.02), PFE: 35.44 (+0.29), LLY: 81.56 (-0.86), GSK: 44.89 (-0.19), ACUR: 1.85 (-0.01), JNJ: 124.24 (+0.38), INSY: 17.62 (+0.32), TRGT: 0.96 (-1.25), GILD: 80.41 (+0.64), AZN: 34.28 (-0.02), ABBV: 66.54 (+0.44), ARNA: 1.74 (+0.03)
Indivior PLC Announces Positive Top-line Results From Pivotal Phase 3 Trial of RBP-7000 in Schizophrenia
PR Newswire - Tue May 05, 6:00AM CDT
Indivior PLC (LON: INDV) today announced top-line results from its phase 3 clinical trial of RBP-7000, an investigational drug in development for the treatment of schizophrenia. In this pivotal study, both doses of RBP-7000 tested, 90 mg and 120 mg administered once-monthly, met the primary endpoint with statistically and clinically significant reductions in the symptoms of acute schizophrenia over an 8-week treatment period. Symptom reduction was measured using the change from baseline to end of treatment in the total Positive and Negative Syndrome Scale (PANSS) scores. RBP-7000 also met the key secondary endpoint with statistically significant improvements in the Clinical Global Impression-Severity of Illness (CGI-S) scale compared with placebo over the 8-week treatment period using change from baseline to end of treatment.
